Skip to content

Careers
Contact Us
Search for:

Home
About
- The COUR Team
- Medical & Science Partners
Technology
- Cour Nanoparticle Platform
Therapeutic Areas
Pipeline
Partners & Collaborators
News & Publications
Videos

Cour Pharmaceuticals

Home > News & Publications > Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Share
Print

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Posted December 4, 2015April 19, 2021 Axxiem

Post navigation

⟵Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium

Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease⟶

Leave a Reply Cancel reply

You must be logged in to post a comment.

888-551-COUR
888-551-2687

Technology

Technology
Cour Nanoparticle Platform

Videos
Technology
Autoimmune Disease
Food and Environmental Allergies
Gene Therapy

Therapeutic Areas

Therapeutic Areas
Autoimmune: Celiac Disease
Food and Environmental Allergies: Peanut
Rare Diseases: Primary Biliary Cholangitis
Gene Therapy

Pipeline

Pipeline
Celiac Disease (CNP-101/TAK-101)
Peanut Allergy (CNP-201)
Primary Biliary Cholangitis (CNP-104)
Gene Therapy (CNP-AAVC)

close ×

About
Partners & Collaborators
News & Publications
Careers
Contact Us
Sitemap
Videos

Website by Axxiem

© Copyright . All Right Reserved

Privacy | Terms of Use